US 12,214,025 B2
Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
Toni Weinschenk, Aichwald (DE); Jens Fritsche, Dusslingen (DE); Harpreet Singh, Munich (DE); Andrea Mahr, Tuebingen (DE); Martina Ott, Tuebingen (DE); Claudia Wagner, Tuebingen (DE); and Oliver Schoor, Tuebingen (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed on May 21, 2021, as Appl. No. 17/327,190.
Application 17/327,190 is a continuation of application No. 17/229,556, filed on Apr. 13, 2021, granted, now 11,116,826.
Application 17/229,556 is a continuation of application No. 16/911,069, filed on Jun. 24, 2020, granted, now 11,007,257, issued on May 18, 2021.
Application 16/911,069 is a continuation of application No. 16/851,627, filed on Apr. 17, 2020, granted, now 10,792,350, issued on Oct. 6, 2020.
Application 16/851,627 is a continuation of application No. 16/748,350, filed on Jan. 21, 2020, granted, now 10,668,138, issued on Jun. 2, 2020.
Application 16/748,350 is a continuation of application No. 16/563,151, filed on Sep. 6, 2019, granted, now 10,576,135, issued on Mar. 3, 2020.
Application 16/563,151 is a continuation of application No. 16/409,393, filed on May 10, 2019, granted, now 10,449,239, issued on Oct. 22, 2019.
Application 16/409,393 is a continuation of application No. 15/869,471, filed on Jan. 12, 2018, granted, now 10,357,551, issued on Jul. 23, 2019.
Application 15/869,471 is a continuation of application No. 15/073,528, filed on Mar. 17, 2016, granted, now 10,076,560, issued on Sep. 18, 2018.
Claims priority of provisional application 62/134,253, filed on Mar. 17, 2015.
Claims priority of application No. 1504502 (GB), filed on Mar. 17, 2015.
Prior Publication US 2021/0322527 A1, Oct. 21, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); C07K 16/18 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); C07K 7/00 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 35/17 (2013.01); A61K 39/001174 (2018.08); A61K 39/001193 (2018.08); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); C07K 14/4748 (2013.01); C07K 14/70539 (2013.01); C07K 16/18 (2013.01); C12N 5/0636 (2013.01); C12N 15/115 (2013.01); A61K 38/00 (2013.01); C07K 7/00 (2013.01); C07K 2319/00 (2013.01); C12N 2310/16 (2013.01)] 17 Claims
 
1. An isolated peptide consisting of the amino acid sequence HLMDQPLSV (SEQ ID NO: 21) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.